[go: up one dir, main page]

PE20050307A1 - 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden - Google Patents

2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden

Info

Publication number
PE20050307A1
PE20050307A1 PE2004000245A PE2004000245A PE20050307A1 PE 20050307 A1 PE20050307 A1 PE 20050307A1 PE 2004000245 A PE2004000245 A PE 2004000245A PE 2004000245 A PE2004000245 A PE 2004000245A PE 20050307 A1 PE20050307 A1 PE 20050307A1
Authority
PE
Peru
Prior art keywords
benzamide
propyl
metoxipiridin
butil
sulfonylamino
Prior art date
Application number
PE2004000245A
Other languages
English (en)
Inventor
Joachim Brendel
Heinz Gogelein
Klaus Wirth
Gert Ulrich Kurzel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050307A1 publication Critical patent/PE20050307A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A 2-(BUTIL-1-SULFONILAMINO)-N-[1(R)-(6-METOXIPIRIDIN-3-IL)PROPIL]-BENZAMIDA, INCLUYENDO SUS SALES FISIOLOGICAMENTE TOLERABLES Y EL USO DE ESTE COMPUESTO COMO UN MEDICAMENTO PARA LA TERAPIA O PROFILAXIS DE ARRITMIAS CARDIACAS, ARRITMIAS SUPRAVENTRICULARES, FIBRILACION AURICULAR Y/O ALETEOS AURICULARES. TAMBIEN SE REFIERE AL USO DEL COMPUESTO 1(R)-(6-METOXIPIRIDIN-3-IL)PROPILAMINA COMO INTERMEDIARIO PARA LA PREPARACION DEL COMPUESTO 2-(BUTIL-1-SULFONILAMINO)-N-[1(R)-(6-METOXIPIRIDIN-3-IL)PROPIL]-BENZAMIDA
PE2004000245A 2003-03-18 2004-03-05 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden PE20050307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
PE20050307A1 true PE20050307A1 (es) 2005-06-08

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000245A PE20050307A1 (es) 2003-03-18 2004-03-05 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden

Country Status (21)

Country Link
EP (1) EP1606237A1 (es)
JP (1) JP2006520343A (es)
KR (1) KR20050110681A (es)
CN (1) CN100361943C (es)
AR (1) AR043622A1 (es)
AU (1) AU2004222137A1 (es)
BR (1) BRPI0408441A (es)
CA (1) CA2519022A1 (es)
DE (1) DE10312073A1 (es)
HR (1) HRP20050815A2 (es)
MA (1) MA27749A1 (es)
MX (1) MXPA05009763A (es)
MY (1) MY176510A (es)
NO (1) NO20054472L (es)
NZ (1) NZ542476A (es)
PE (1) PE20050307A1 (es)
RS (1) RS20050690A (es)
RU (1) RU2333202C2 (es)
TW (1) TW200500342A (es)
WO (1) WO2004083157A1 (es)
ZA (1) ZA200506328B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
US9101616B2 (en) * 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
ZA200506328B (en) 2006-04-26
AR043622A1 (es) 2005-08-03
CA2519022A1 (en) 2004-09-30
CN1756728A (zh) 2006-04-05
DE10312073A1 (de) 2004-09-30
CN100361943C (zh) 2008-01-16
RU2005132163A (ru) 2006-04-10
NZ542476A (en) 2008-05-30
KR20050110681A (ko) 2005-11-23
JP2006520343A (ja) 2006-09-07
MY176510A (en) 2020-08-12
AU2004222137A1 (en) 2004-09-30
HK1086819A1 (en) 2006-09-29
MA27749A1 (fr) 2006-02-01
RS20050690A (sr) 2008-04-04
TW200500342A (en) 2005-01-01
BRPI0408441A (pt) 2006-04-04
HRP20050815A2 (en) 2006-09-30
MXPA05009763A (es) 2006-01-27
RU2333202C2 (ru) 2008-09-10
WO2004083157A1 (de) 2004-09-30
NO20054472L (no) 2005-09-27
EP1606237A1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
LV12632A (lv) Pyrazoline derivatives their preparation and application as medicaments
BRPI0409109A (pt) novos compostos
PA8547701A1 (es) Nucleosidos 4 substituidos.
AR031430A1 (es) Compuestos de bisarilo orto, meta-sustituidos, procedimientos para su preparacion, su utilizacion como medicamento como tambien los preparados farmaceuticos que los contienen
BR0312729A (pt) Novos derivados de indol-3-enxofre
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR0210374A (pt) Amidas de ácido antranìlico com cadeia lateral de heteroarilsulfonila, processos para produção das mesmas, uso das mesmas como medicamento ou agente de diagnóstico, bem como preparações farmacêuticas que contêm as mesmas
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
HN2000000050A (es) Sal mutua de amlodipino y atorvastatina
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
AR039633A2 (es) Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
AR033659A1 (es) El compuesto 2-(3,5-bis -trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida), su uso, un procedimiento para prepararlo y un medicamento que lo contiene
ES2163735T3 (es) Compuestos biarilos heterociclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
HN2000000075A (es) Profarmacos mutuos amlodipino y atorvastatina
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
PE20050307A1 (es) 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metoxipiridin-3-il)propil]benzamida, su uso como un medicamento y preparaciones farmaceuticas que lo comprenden
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
ES2177671T3 (es) Benzamida enterocinetica.
AR037427A1 (es) Compuesto de quinolina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento para prepararlo y compuestos de quinolina de utilidad como intermediarios en dicho procedimiento
UY27910A1 (es) Uso de un derivado de amina cíclica específico o de sus sales farmacéuticamente aceptables para tratar o prevenir la insuficiencia cardiaca

Legal Events

Date Code Title Description
FC Refusal